Juvena Therapeutics develops tissue-restorative biologics to address chronic muscle and age-related conditions.
Juvena Therapeutics has raised $33.5M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Juvena Therapeutics's investors include Alumni Ventures, Eli Lilly, Mubadala Capital, Felicis, Liquid 2 Ventures.
Juvena Therapeutics is headquartered in Palo Alto, United States.
Juvena Therapeutics develops tissue-restorative biologics to address chronic muscle and age-related conditions.
Juvena Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Juvena Therapeutics — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/juvena-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Juvena Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/juvena-therapeutics
{{cite web |title=Juvena Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/juvena-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated